Prasugrel a better choice to improve outcomes in ACS patients with CKD, JACC study. dr. Abhimanyu Uppal25 Aug 2021 10:00 AM ISTChronic kidney disease (CKD) represents a puzzling dilemma for physicians who care for patients experiencing acute coronary syndrome (ACS). The...
The Dilemma of dissection: JACC review summarizes "clinical pearls" of SCAD diagnosis. dr. Abhimanyu Uppal21 Aug 2021 9:30 AM ISTSpontaneous coronary artery dissection (SCAD) is a pathophysiologically distinct cause of acute coronary syndromes (ACS). A recent JACC review...
Acute coronary syndrome managed effectively by de-escalation method in DAPT: JACC Dr Satabdi Saha28 July 2021 9:15 AM ISTDe-escalation was the most effective strategy for ACS treatment when compared with other established uses of DAPT, resulting in fewer bleeding events...
Smoking linked to increased heart diseases in younger population: MD Editorial Team21 July 2021 9:00 AM ISTCardiovascular diseases are one of the major causes of death worldwide, with 2380 deaths per day as per recent statistics. A recent tertiary care...
One third Patients of ACS potentially eligible for PCSK9 Inhibitors Treatment, finds study MD Bureau19 May 2021 9:00 AM ISTPrevious studies have shown that the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors evolocumab and alirocumab have been associated...
Study casts doubt on Ticagrelor's superiority over Clopidogrel in real-world scenario. dr. Abhimanyu Uppal22 April 2021 8:45 AM ISTTicagrelor had established itself as the go-to P2Y12 inhibitor for the treatment of acute coronary syndromes (ACS) based on the results of the PLATO...
Single troponin test enough to discharge suspected heart attack patients from ED: JAMA Medha Baranwal26 Feb 2021 8:25 PM ISTUSA: A single negative troponin test versus serial troponin testing appears safe in ruling out acute coronary syndrome (ACS) in patients presented to...
Dissolving the dilemma: Management of Antithrombotic Therapy after Acute Coronary Syndromes dr. Abhimanyu Uppal24 Feb 2021 9:00 AM ISTThe management of antithrombotic agents for patients after an acute coronary syndrome is becoming increasingly complex. The data suggesting better...
LDL-C level reduction <25 mg/dL with alirocumab not tied to MACE reduction: Circulation Medha Baranwal29 Jan 2021 9:27 PM ISTUSA: Acute coronary syndrome (ACS) patients treated with alirocumab who achieved LDL-C levels <25 mg/dL versus 25–50 mg/d did not show any...
Tricaglor not linked to better outcomes in ACS after PCI compared to clopiogril: JAMA Medha Baranwal2 Nov 2020 9:15 AM ISTUSA: The use of ticagrelor over clopidogrel, in ACS patients treated with PCI do not lead to better clinical outcomes, suggests a recent study in...
Reduced-dose prasugrel lowers bleeding risk in elderly ACS patients: Study Medha Baranwal8 Sept 2020 6:00 PM ISTGermany: A reduced dose of prasugrel versus standard dose of ticagrelor helped in maintaining anti-ischemic efficacy in elderly or...
Apabetalone did not reduce MACE risk in patients of ACS with diabetes Dr. Kamal Kant Kohli2 May 2020 9:45 AM ISTResearchers have found that Apabetalone did not significantly reduce major adverse cardiovascular events after acute coronary syndrome with Type 2...
